The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients

Arthritis and Rheumatism

Volumn 44, Issue 11, 2001, Pages 2525-2530

  Van Ede, Annelies E ^a   Laan, Roland F J M ^a   Blom, Henk J ^a   Huizinga, Tom W J ^b   Haagsma, Cees J ^c   Giesendorf, Belinda A J ^a   De Boo, Theo M ^a   Van De Putte, Leo B A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE AMINOTRANSFERASE; FOLIC ACID; HOMOCYSTEINE; LIVER ENZYME; METHOTREXATE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC RISK; GENOTYPE; HAIR LOSS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEMATINICS; HUMANS; LIVER; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0035157121     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200111)44:11<2525::AID-ART432>3.0.CO;2-B     Document Type: Article

References (16)

1. Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved in toxicity
2. The mechanism of action of methotrexate
3. Methotrexate: Mechanism of action, pharmacokinetics, clinical indications and toxicity
4. The cellular pharmacology of methotrexate
5. Methionine metabolism in mammals
6. A candidate genetic risk for vascular disease: A common mutation in methylenetetrahydrofolate reductase
7. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia
8. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
9. Effect of folic or folinic acid supplementation on toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study
10. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score
11. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis
12. A toxicity index for comparison of side effects among different drugs
13. Molecular beacons: A new approach for semiautomated mutation analysis
14. Is the common 677C→T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A mega-analysis
15. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis
16. Prospectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: Relation to withdrawal and side effects